| Document |
Document Title |
|
WO/2024/079733A1 |
The present invention provides a process for the preparation of aminopyridazine derivatives, and novel pyridazine-based and pyrazole-based compounds which are useful as either starting materials or intermediates in said process.
|
|
WO/2024/079291A1 |
The inventors have now succeeded in developing novel compounds comprising a diphenylpyrazole scaffold bearing amino side chains. These compounds have the advantage of repressing the production of Aβ1-x and modulating the ratio of autoph...
|
|
WO/2024/078513A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of a disorder, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2024/077487A1 |
The invention relates to a process for separating the solution mixture, characterized in that the solution mixture comprises a base, an organic solvent, water and the compound of formula (I) the process comprises the distillation of the ...
|
|
WO/2024/081410A1 |
In certain embodiments, the invention is directed to a compound of formula (I): wherein; X1 is selected from N or N+Y1; X2 is selected from NH or NY2; X3 is selected from NH or NY3; Y1 is selected from -CH2OCO(OCH2CH2)n1OM1; or -CH2OCO(C...
|
|
WO/2024/075051A1 |
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD an...
|
|
WO/2024/067773A1 |
Provided herein are compounds and methods for modulating or inhibiting TEAD. Further provided herein are pharmaceutical compositions comprising the TEAD inhibitors and methods of treatment using the TEAD inhibitors or the pharmaceutical ...
|
|
WO/2024/066981A1 |
Provided in the present invention are deuterated pyrazole derivatives, of which the structures are represented as formula (I). Further disclosed in the present invention are pharmaceutically acceptable salts and stereoisomers of the deri...
|
|
WO/2024/071629A1 |
The present invention relates to a novel fluorene derivative compound, and a use thereof in the prevention or treatment of metabolic diseases and/or cancer diseases through the action thereof as a PDK4 inhibitor.
|
|
WO/2024/068853A1 |
The present invention relates to an improved synthesis of Otviciclib (N-{4-[l-(2,6-Dichloro-4- sulfamoyl-phenyl)-3-dimethylamino-4-oxo-4,5-dihydro-lH-pyraz
olo[3,4-d]pyrimidin-6- ylmethyl]-phenyl}-2-diethylamino-acetamide) and its deriva...
|
|
WO/2024/064655A1 |
The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including n...
|
|
WO/2024/063147A1 |
The present invention provides a compound represented by formula (I) and useful as a pharmaceutical product, or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition for the treat...
|
|
WO/2024/061768A1 |
The invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof, wherein the variables are defined according to the description. The compounds ...
|
|
WO/2024/056019A1 |
Disclosed herein are bicyclic compound derivatives used as inhibitors of cyclin-dependent kinases. Disclosed herein is the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of such compounds for treating cancer.
|
|
WO/2024/055801A1 |
The present invention relates to a pyridinamide derivative and a use thereof, and specifically relates to a compound of formula (I) or an isotope labeled compound thereof as a pyridinamide derivative, or an optical isomer, a geometric is...
|
|
WO/2024/059659A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, Y1, Y2, X1, X2, X3, Q1, and Ra are as defined elsewhere herein. Also provid...
|
|
WO/2024/059661A1 |
Provided herein are compounds of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R1, R2, R3, R4, Y1, Y2, X1, X2, L, and Q1 are as defined elsewhere herein. A...
|
|
WO/2024/057020A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2024/052702A1 |
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein RL, L and RR, and any groups associated therewith, are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha...
|
|
WO/2024/054876A1 |
The present disclosure relates to bifunctional compounds that cause the degradation of LRRK2; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with LRRK2, including Parkinson's Disease.
|
|
WO/2023/160569A9 |
This disclosure relates to compounds of Formula (I) as PGE2 receptor antagonists or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/049748A1 |
An improved method is disclosed for preparing a 3-halo-4,5-dihydro-1H-pyrazole compound of Formula I comprising reacting a compound of Formula II with a halide salt and a mineral acid to form the compound of Formula I. wherein X1, R1, R2...
|
|
WO/2024/044848A1 |
The present application relates to indazole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
|
WO/2024/040995A1 |
The present application relates to a synthesis method for an N-methyl-3-substituted methyl-4-pyrazolecarboxamide derivative and N-methyl-3-substituted methyl-4-pyrazolecarboxylic acid, the method comprising the following steps: S1: synth...
|
|
WO/2024/038471A1 |
ORAL FORMULATIONS OF EDARAVONE AND IMPROVED METHOD OF MANUFACTURING THEREOF The present invention relates to a powder for oral suspension dosage form of Edaravone. The invention also relates to provide patient-compliant, economical and t...
|
|
WO/2024/039250A1 |
The present invention relates to a new class of methanogen inhibitors for ruminants. The invention also extends to the use of such compounds in ruminants to reduce methane production in the rumen and/or to enhance productivity in the rum...
|
|
WO/2024/032597A1 |
A compound having a STING inhibitory effect or a pharmaceutically acceptable salt thereof, and a use thereof in the preparation of a drug for treating diseases related to abnormal STING expression. Specifically disclosed are compounds of...
|
|
WO/2024/036243A2 |
Disclosed herein are new salts of substituted pyrazole compounds which inhibit the activity of the monocarboxylate transporter MCT4, or a mutant thereof. Also disclosed herein are compounds, pharmaceutical compositions, and methods of tr...
|
|
WO/2024/035085A1 |
The present invention relates to a novel compound, and a composition for preventing or treating HER2-positive cancer, comprising same. The novel compound of the present invention can suppress the level of HER2 by inhibiting the protein-p...
|
|
WO/2024/032584A1 |
The present invention relates to a protein tyrosine kinase inhibitor for treating protein tyrosine kinase-mediated proliferative diseases or symptoms, such as ocular diseases and malignant tumors accompanied by pathological neoangiogenes...
|
|
WO/2024/033322A1 |
The present invention relates to a metal complex, a semiconductor layer comprising the metal complex and an organic electronic device comprising at least one metal complex thereof.
|
|
WO/2024/030504A1 |
The invention provides methods of treating patients with Parkinson's disease (PD) associated with wild-type LRRK2. The invention recognizes that analysis of biomarkers in such patients allows identification of those patients who will res...
|
|
WO/2024/028808A1 |
The present disclosure relates to compounds of Formula (I) which modulate the activity of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, au...
|
|
WO/2024/030529A1 |
Disclosed are prodrugs of MYC inhibitors and methods making and using same.
|
|
WO/2024/028601A1 |
The present invention relates to compounds of formula I as prostaglandin E2 receptor 4 (EP4) agonists for use in methods of treatment of gastrointestinal and pulmonary diseases or disorders. An exemplary compound is e.g. 4-(2-(2-(3-hydro...
|
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
|
WO/2024/026359A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for ...
|
|
WO/2024/026512A2 |
Disclosed are substituted heterocyclic compounds and proteolysis-targeting chimeric molecules (PROTACs). The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC. The disclosed PROTACs are shown to induce ...
|
|
WO/2024/025907A1 |
The present disclosure provides compounds of Formula (IA) and their pharmaceutical compositions: The compounds and compositions are useful for inhibiting the activity of plasma kallikrein, and they are useful in therapy and in methods of...
|
|
WO/2024/024760A1 |
The purpose of the present invention is to provide a highly stable pyrazolone compound. This problem can be solved by a pyrazolone compound represented by formula (1) of the present invention (in the formula, R1 is an electron-withdraw...
|
|
WO/2023/250157A9 |
Disclosed are compounds for inhibiting lipoamide dehydrogenase (Lpd), and methods of treating tuberculosis.
|
|
WO/2024/018290A1 |
The present invention relates to a stable synergistic pesticidal composition capable of protecting plant propagation materials such seeds, seedlings; and plants/crops from harmful effects of seed-borne, soil borne pathogenic fungi and/or...
|
|
WO/2024/017788A1 |
The present invention relates to a crystalline polymorph of the compound of formula (I), which has a powder X-ray diffraction pattern comprising at least three 2θ angle values selected from the group consisting of 7.2 ± 0.2°, 10.8 ± ...
|
|
WO/2024/011414A1 |
Disclosed in the present invention is a reaction method for secondary amine and o-diiodobenzene, comprising: reacting secondary amine with o-diiodobenzene in the presence of an alkali metal hydride or a Grignard reagent to complete the r...
|
|
WO/2024/012496A1 |
Provided in the present invention is a cannabinoid receptor compound as represented by formula I. The compound has good binding capacity and inverse agonistic activity on a human CB1 receptor, and almost does not display the inverse agon...
|
|
WO/2023/280638A9 |
The application relates to vinyl thianthrenium compounds Vinyl- TT+X- of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.
|
|
WO/2024/012791A1 |
The present invention relates to an electrochemical process for the synthesis of pyrazolines and pyrazoles of formula (I). The process can be especially used for the synthesis of the herbicide safener mefenpyr-diethyl.
|
|
WO/2024/009283A1 |
Angiotensin AT2 receptor antagonists have been clinically validated for the treatment of chronic neuropathic pain. We discovered a series of lead compounds comprising a trisubstituted heterocyclic core that show high in vitro (sub-nanomo...
|
|
WO/2024/007976A1 |
A compound represented by formula (I), a chiral enantiomer thereof or pharmaceutically acceptable salts thereof, and a preparation method therefor, an intermediate used for preparing the compound represented by formula (I), the chiral en...
|
|
WO/2024/001487A1 |
The present invention relates to the technical field of green, clean and efficient catalysis, and in particular, to a method for synthesizing a cyclic carbonate from carbon dioxide and an epoxy compound by means of a catalytic reaction a...
|
